| 糖尿病是可切除胰腺导管腺癌的预后因子 |
| |
| 引用本文： | 董茜,荆薇,杨向红,刘云鹏,曲秀娟. 糖尿病是可切除胰腺导管腺癌的预后因子[J]. 中国肿瘤临床, 2014, 41(15): 979-983. DOI: 10.3969/j.issn.1000-8179.20131565 |
| |
| 作者姓名： | 董茜 荆薇 杨向红 刘云鹏 曲秀娟 |
| |
| 作者单位： | ①.中国医科大学附属盛京医院肿瘤科（沈阳市 110022） |
| |
| 摘 要： | 目的 探讨合并2型糖尿病与胰腺导管腺癌（pancreatic ductal adenocarcinoma，PDAC）患者的临床病理因素及其与预后的关系。 方法 回顾性分析2009年1月至2011年2月可手术切除PDAC患者的临床病理资料，进行生存分析。 结果 136例PDAC患者中合并糖尿病的比率为27.9%，糖尿病与各临床病理特征均无关（均P>0.05）。单因素分析显示:糖尿病、肿瘤最大直径、组织学分化程度、pT分期、脉管侵润及pTNM分期，均与PDAC患者预后显著相关（均P < 0.05）。多因素分析显示:合并糖尿病（HR，1.873；P=0.007），组织学低分化肿瘤（HR=2.647；P=0.002）及肿瘤最大直径≥4.0 cm（HR=1.699；P=0.018），均是独立预后因子。 结论 合并糖尿病是可手术切除的PDAC患者预后差的独立预测因子。
|
| 关 键 词： | 胰腺导管腺癌 2型糖尿病 预后 总生存期 |
| 收稿时间： | 2013-09-17 |
Type 2 diabetes mellitus is a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma |
| |
| Affiliation: | ①.Department of Oncology, the First Affiliated Hospital of China Medical University, Shenyang 110001, China②.Department of Pathology, Shengjing Hospital of China Medical University, Shenyang 110022, China③.Department of Oncology, the First Affiliated Hospital of China Medical University, Shenyang 110001, China |
| |
| Abstract: | Objective Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal human cancers. Current studies on the relationship between complicated type 2 diabetes mellitus (T2DM) and PDAC prognosis have demonstrated inconsistent results. The present study aimed to determine the relationship between complicated T2DM and the clinicopathological characteristics of PDAC, and evaluate whether complicated T2DM is a significant predictor for overall survival in patients with resectable PDAC Methods In this study, clinicopathological characteristics were observed in 136 patients who underwent surgery for PDAC at the Shengjing Hospital of China Medical University between January 2009 and February 2011. The relationship between complicated T2DM and overall survival of PDAC patients was analyzed using univariate and multivariate analyses. Results The median age of patients was 60 years (range: 35-80 years). Among the 136 patients, 76(55.9%) were male. The prevalence of complicated T2DM was 27.9% in 136 PDAC cases. Preexisting T2DM was not associated with any of the clinicopathological characteristics (all P>0.05). Univariate analysis showed that complicated T2DM (P=0.045), maximum diameter (P=0.011), histological differentiation (P=0.013), pT stage (P=0.034), vessel invasion (P=0.032), and pTNM stage (P=0.030) were significantly associated with the overall survival of PDAC patients. The median overall survival time was 14.2 months for T2DM patients, and 18.8 months for non-T2DM patients. In multivariate analysis, complicated T2DM [hazard ratio (HR), 1.873; 95% confidence interval (CI), 1.187-2.954; P=0.007], poorly differentiated tumor (HR, 2.647; 95% CI, 1.413-4.957; P=0.002), and maximum diameter ≥4.0 cm (HR, 1.699; 95% CI, 1.094-2.640; P=0.018) were the independent predictors associated with poor overall survival. Conclusion Complicated T2DM was associated with poor prognosis. It could be used as a prognostic predictor in patients with resectable PDAC. If confirmed, these findings may provide a novel approach for individualized adjuvant therapy. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
